Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Andrew Berchuck

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Concepts & Ideas

Physiology

Procedures

Chemicals & Drugs

Anatomy

Cultured Tumor Cells

Genes & Molecular Sequences

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Jewell Elizabeth L; Darcy Kathleen M; Hutson Alan; Lee Paula S; Havrilesky Laura J; Grace Lisa A; Berchuck Andrew; Secord Angeles Alvarez
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
Cunningham J M; Vierkant R A; Sellers T A; Phelan C; Rider D N; Liebow M; Schildkraut J; Berchuck A; Couch F J; Wang X; Fridley B L; Gentry-Maharaj A; Menon U; Hogdall E; Kjaer S; Whittemore A; DiCioccio R; Song H; Gayther S A; Ramus S J; Pharaoh P D P; Goode E L
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.
Song Honglin; Ramus Susan J; Tyrer Jonathan; Bolton Kelly L; Gentry-Maharaj Aleksandra; Wozniak Eva; Anton-Culver Hoda; Chang-Claude Jenny; Cramer Daniel W; DiCioccio Richard; Dörk Thilo; Goode Ellen L; Goodman Marc T; Schildkraut Joellen M; Sellers Thomas; Baglietto Laura; Beckmann Matthias W; Beesley Jonathan; Blaakaer Jan; Carney Michael E; Chanock Stephen; Chen Zhihua; Cunningham Julie M; Dicks Ed; Doherty Jennifer A; Dürst Matthias; Ekici Arif B; Fenstermacher David; Fridley Brooke L; Giles Graham; Gore Martin E; De Vivo Immaculata; Hillemanns Peter; Hogdall Claus; Hogdall Estrid; Iversen Edwin S; Jacobs Ian J; Jakubowska Anna; Li Dong; Lissowska Jolanta; Lubinski Jan; Lurie Galina; McGuire Valerie; McLaughlin John; Medrek Krzysztof; Moorman Patricia G; Moysich Kirsten; Narod Steven; Phelan Catherine; Pye Carole; Risch Harvey; Runnebaum Ingo B; Severi Gianluca; Southey Melissa; Stram Daniel O; Thiel Falk C; Terry Kathryn L; Tsai Ya-Yu; Tworoger Shelley S; Van Den Berg David J; Vierkant Robert A; Wang-Gohrke Shan; Webb Penelope M; Wilkens Lynne R; Wu Anna H; Yang Hannah; Brewster Wendy; Ziogas Argyrios; Houlston Richard; Tomlinson Ian; Whittemore Alice S; Rossing Mary Anne; Ponder Bruce A J; Pearce Celeste Leigh; Ness Roberta B; Menon Usha; Kjaer Susanne Krüger; Gronwald Jacek; Garcia-Closas Montserrat; Fasching Peter A; Easton Douglas F; Chenevix-Trench Georgia; Berchuck Andrew; Pharoah Paul D P; Gayther Simon A
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Andrew Berchuck (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Jewell Elizabeth L; Darcy Kathleen M; Hutson Alan; Lee Paula S; Havrilesky Laura J; Grace Lisa A; Berchuck Andrew; Secord Angeles Alvarez
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
Gynecologic oncology 2009;115(3):424-9.
2009: Cunningham J M; Vierkant R A; Sellers T A; Phelan C; Rider D N; Liebow M; Schildkraut J; Berchuck A; Couch F J; Wang X; Fridley B L; Gentry-Maharaj A; Menon U; Hogdall E; Kjaer S; Whittemore A; DiCioccio R; Song H; Gayther S A; Ramus S J; Pharaoh P D P; Goode E L
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.
British journal of cancer 2009;101(8):1461-8.
2009: Song Honglin; Ramus Susan J; Tyrer Jonathan; Bolton Kelly L; Gentry-Maharaj Aleksandra; Wozniak Eva; Anton-Culver Hoda; Chang-Claude Jenny; Cramer Daniel W; DiCioccio Richard; Dörk Thilo; Goode Ellen L; Goodman Marc T; Schildkraut Joellen M; Sellers Thomas; Baglietto Laura; Beckmann Matthias W; Beesley Jonathan; Blaakaer Jan; Carney Michael E; Chanock Stephen; Chen Zhihua; Cunningham Julie M; Dicks Ed; Doherty Jennifer A; Dürst Matthias; Ekici Arif B; Fenstermacher David; Fridley Brooke L; Giles Graham; Gore Martin E; De Vivo Immaculata; Hillemanns Peter; Hogdall Claus; Hogdall Estrid; Iversen Edwin S; Jacobs Ian J; Jakubowska Anna; Li Dong; Lissowska Jolanta; Lubinski Jan; Lurie Galina; McGuire Valerie; McLaughlin John; Medrek Krzysztof; Moorman Patricia G; Moysich Kirsten; Narod Steven; Phelan Catherine; Pye Carole; Risch Harvey; Runnebaum Ingo B; Severi Gianluca; Southey Melissa; Stram Daniel O; Thiel Falk C; Terry Kathryn L; Tsai Ya-Yu; Tworoger Shelley S; Van Den Berg David J; Vierkant Robert A; Wang-Gohrke Shan; Webb Penelope M; Wilkens Lynne R; Wu Anna H; Yang Hannah; Brewster Wendy; Ziogas Argyrios; Houlston Richard; Tomlinson Ian; Whittemore Alice S; Rossing Mary Anne; Ponder Bruce A J; Pearce Celeste Leigh; Ness Roberta B; Menon Usha; Kjaer Susanne Krüger; Gronwald Jacek; Garcia-Closas Montserrat; Fasching Peter A; Easton Douglas F; Chenevix-Trench Georgia; Berchuck Andrew; Pharoah Paul D P; Gayther Simon A
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.
Nature genetics 2009;41(9):996-1000.
2009: Moorman Patricia G; Palmieri Rachel T; Akushevich Lucy; Berchuck Andrew; Schildkraut Joellen M
Ovarian cancer risk factors in African-American and white women.
American journal of epidemiology 2009;170(5):598-606.
2009: Ding X; Mohd A B; Huang Z; Baba T; Bernardini M Q; Lyerly H K; Berchuck A; Murphy S K; Buermeyer A B; Devi G R
MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.
British journal of cancer 2009;101(2):269-77.
2009: Bernardini Marcus Q; May Taymaa; Khalifa Mahmoud A; Bland Amy E; Nofech-Mozes Sharon; Berchuck Andrew; Covens Al; Havrilesky Laura
Evaluation of two management strategies for preoperative grade 1 endometrial cancer.
Obstetrics and gynecology 2009;114(1):7-15.
2009: Berchuck Andrew
Microarray analysis of gene expression in gynecologic cancers--still only the beginning.
Gynecologic oncology 2009;114(1):1-2.
2009: Song Honglin; Ramus Susan J; Kjaer Susanne Krüger; DiCioccio Richard A; Chenevix-Trench Georgia; Pearce Celeste Leigh; Hogdall Estrid; Whittemore Alice S; McGuire Valerie; Hogdall Claus; Blaakaer Jan; Wu Anna H; Van Den Berg David J; Stram Daniel O; Menon Usha; Gentry-Maharaj Aleksandra; Jacobs Ian J; Webb Penny M; Beesley Jonathan; Chen Xiaoqing; Rossing Mary Anne; Doherty Jennifer A; Chang-Claude Jenny; Wang-Gohrke Shan; Goodman Marc T; Lurie Galina; Thompson Pamela J; Carney Michael E; Ness Roberta B; Moysich Kirsten; Goode Ellen L; Vierkant Robert A; Cunningham Julie M; Anderson Stephanie; Schildkraut Joellen M; Berchuck Andrew; Iversen Edwin S; Moorman Patricia G; Garcia-Closas Montserrat; Chanock Stephen; Lissowska Jolanta; Brinton Louise; Anton-Culver Hoda; Ziogas Argyrios; Brewster Wendy R; Ponder Bruce A J; Easton Douglas F; Gayther Simon A; Pharoah Paul D P;
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.
Human molecular genetics 2009;18(12):2297-304.
2009: Fasching Peter A; Gayther Simon; Pearce Leigh; Schildkraut Joellen M; Goode Ellen; Thiel Falk; Chenevix-Trench Georgia; Chang-Claude Jenny; Wang-Gohrke Shan; Ramus Susan; Pharoah Paul; Berchuck Andrew;
Role of genetic polymorphisms and ovarian cancer susceptibility.
Molecular oncology 2009;3(2):171-81.
2009: Berchuck Andrew; Iversen Edwin S; Luo Jingqin; Clarke Jennifer P; Horne Hisani; Levine Douglas A; Boyd Jeff; Alonso Miguel A; Secord Angeles Alvarez; Bernardini Marcus Q; Barnett Jason C; Boren Todd; Murphy Susan K; Dressman Holly K; Marks Jeffrey R; Lancaster Johnathan M
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2448-55.
2009: Schildkraut Joellen M; Goode Ellen L; Clyde Merlise A; Iversen Edwin S; Moorman Patricia G; Berchuck Andrew; Marks Jeffrey R; Lissowska Jolanta; Brinton Louise; Peplonska Beata; Cunningham Julie M; Vierkant Robert A; Rider David N; Chenevix-Trench Georgia; Webb Penelope M; Beesley Jonathan; Chen Xiaoqing; Phelan Catherine; Sutphen Rebecca; Sellers Thomas A; Pearce Leigh; Wu Anna H; Van Den Berg David; Conti David; Elund Christopher K; Anderson Rebecca; Goodman Marc T; Lurie Galina; Carney Michael E; Thompson Pamela J; Gayther Simon A; Ramus Susan J; Jacobs Ian; Krüger Kjaer Susanne; Hogdall Estrid; Blaakaer Jan; Hogdall Claus; Easton Douglas F; Song Honglin; Pharoah Paul D P; Whittemore Alice S; McGuire Valerie; Quaye Lydia; Anton-Culver Hoda; Ziogas Argyrios; Terry Kathryn L; Cramer Daniel W; Hankinson Susan E; Tworoger Shelley S; Calingaert Brian; Chanock Stephen; Sherman Mark; Garcia-Closas Montserrat;
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.
Cancer research 2009;69(6):2349-57.
2009: Rubatt Jennifer M; Darcy Kathleen M; Hutson Alan; Bean Sarah M; Havrilesky Laura J; Grace Lisa A; Berchuck Andrew; Secord Angeles Alvarez
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Gynecologic oncology 2009;112(3):469-74.
2009: Matsumura Noriomi; Huang Zhiqing; Baba Tsukasa; Lee Paula S; Barnett Jason C; Mori Seiichi; Chang Jeffrey T; Kuo Wen-Lin; Gusberg Alison H; Whitaker Regina S; Gray Joe W; Fujii Shingo; Berchuck Andrew; Murphy Susan K
Yin yang 1 modulates taxane response in epithelial ovarian cancer.
Molecular cancer research : MCR 2009;7(2):210-20.
2009: Hakim Amy A; Barry Catherine P; Barnes H John; Anderson Kenneth E; Petitte James; Whitaker Regina; Lancaster Jonathan M; Wenham Robert M; Carver Donna K; Turbov Jane; Berchuck Andrew; Kopelovich Levy; Rodriguez Gustavo C
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
Cancer prevention research (Philadelphia, Pa.) 2009;2(2):114-21.
2009: Pearce C L; Near A M; Van Den Berg D J; Ramus S J; Gentry-Maharaj A; Menon U; Gayther S A; Anderson A R; Edlund C K; Wu A H; Chen X; Beesley J; Webb P M; Holt S K; Chen C; Doherty J A; Rossing M A; Whittemore A S; McGuire V; DiCioccio R A; Goodman M T; Lurie G; Carney M E; Wilkens L R; Ness R B; Moysich K B; Edwards R; Jennison E; Kjaer S K; Hogdall E; Hogdall C K; Goode E L; Sellers T A; Vierkant R A; Cunningham J C; Schildkraut J M; Berchuck A; Moorman P G; Iversen E S; Cramer D W; Terry K L; Vitonis A F; Titus-Ernstoff L; Song H; Pharoah P D P; Spurdle A B; Anton-Culver H; Ziogas A; Brewster W; Galitovskiy V; Chenevix-Trench G;
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.
British journal of cancer 2009;100(2):412-20.
2009: Bland Amy E; Calingaert Brian; Secord Angeles Alvarez; Lee Paula S; Valea Fidel A; Berchuck Andrew; Soper John T; Havrilesky Laura
Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Gynecologic oncology 2009;112(1):150-4.
2009: Baba T; Convery P A; Matsumura N; Whitaker R S; Kondoh E; Perry T; Huang Z; Bentley R C; Mori S; Fujii S; Marks J R; Berchuck A; Murphy S K
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Oncogene 2009;28(2):209-18.
2008: Palmieri Rachel T; Wilson Melanie A; Iversen Edwin S; Clyde Merlise A; Calingaert Brian; Moorman Patricia G; Poole Charles; Anderson A Rebecca; Anderson Stephanie; Anton-Culver Hoda; Beesley Jonathan; Hogdall Estrid; Brewster Wendy; Carney Michael E; Chen Xiaoqing; Chenevix-Trench Georgia; Chang-Claude Jenny; Cunningham Julie M; Dicioccio Richard A; Doherty Jennifer A; Easton Douglas F; Edlund Christopher K; Gayther Simon A; Gentry-Maharaj Aleksandra; Goode Ellen L; Goodman Marc T; Kjaer Susanne Kruger; Hogdall Claus K; Hopkins Michael P; Jenison Eric L; Blaakaer Jan; Lurie Galina; McGuire Valerie; Menon Usha; Moysich Kirsten B; Ness Roberta B; Pearce Celeste Leigh; Pharoah Paul D P; Pike Malcolm C; Ramus Susan J; Rossing Mary Anne; Song Honglin; Terada Keith Y; Vandenberg David; Vierkant Robert A; Wang-Gohrke Shan; Webb Penelope M; Whittemore Alice S; Wu Anna H; Ziogas Argyrios; Berchuck Andrew; Schildkraut Joellen M;
Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(12):3567-72.
2008: Havrilesky Laura J; Whitehead Clark M; Rubatt Jennifer M; Cheek Robert L; Groelke John; He Qin; Malinowski Douglas P; Fischer Timothy J; Berchuck Andrew
Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Gynecologic oncology 2008;110(3):374-82.
2008: Ramus Susan J; Vierkant Robert A; Johnatty Sharon E; Pike Malcolm C; Van Den Berg David J; Wu Anna H; Pearce Celeste Leigh; Menon Usha; Gentry-Maharaj Aleksandra; Gayther Simon A; Dicioccio Richard A; McGuire Valerie; Whittemore Alice S; Song Honglin; Easton Douglas F; Pharoah Paul D P; Garcia-Closas Montserrat; Chanock Stephen; Lissowska Jolanta; Brinton Louise; Terry Kathryn L; Cramer Daniel W; Tworoger Shelley S; Hankinson Susan E; Berchuck Andrew; Moorman Patricia G; Schildkraut Joellen M; Cunningham Julie M; Liebow Mark; Kjaer Susanne Krüger; Hogdall Estrid; Hogdall Claus; Blaakaer Jan; Ness Roberta B; Moysich Kirsten B; Edwards Robert P; Carney Michael E; Lurie Galina; Goodman Marc T; Wang-Gohrke Shan; Kropp Silke; Chang-Claude Jenny; Webb Penelope M; Chen Xiaoqing; Beesley Jonathan; Chenevix-Trench Georgia; Goode Ellen L;
Consortium analysis of 7 candidate SNPs for ovarian cancer.
International journal of cancer. Journal international du cancer 2008;123(2):380-8.
2008: Berchuck Andrew
Scientific innovation--pathway to progress in women's cancer.
Gynecologic oncology 2008;109(3):316-22.
2008: Moorman Patricia G; Calingaert Brian; Palmieri Rachel T; Iversen Edwin S; Bentley Rex C; Halabi Susan; Berchuck Andrew; Schildkraut Joellen M
Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women.
American journal of epidemiology 2008;167(9):1059-69.
2008: Wright J D; Secord A A; Numnum T M; Rocconi R P; Powell M A; Berchuck A; Alvarez R D; Gibb R K; Trinkaus K; Rader J S; Mutch D G
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(3):400-6.
2008: Schildkraut Joellen M; Moorman Patricia G; Bland Amy E; Halabi Susan; Calingaert Brian; Whitaker Regina; Lee Paula S; Elkins-Williams Tyler; Bentley Rex C; Marks Jeffrey R; Berchuck Andrew
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(3):585-93.
2008: Pearce C L; Wu A H; Gayther S A; Bale A E; Beck P A; Beesley J; Chanock S; Cramer D W; DiCioccio R; Edwards R; Fredericksen Z S; Garcia-Closas M; Goode E L; Green A C; Hartmann L C; Hogdall E; Kjaer S K; Lissowska J; McGuire V; Modugno F; Moysich K; Ness R B; Ramus S J; Risch H A; Sellers T A; Song H; Stram D O; Terry K L; Webb P M; Whiteman D C; Whittemore A S; Zheng W; Pharoah P D P; Chenevix-Trench G; Pike M C; Schildkraut J; Berchuck A;
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis.
British journal of cancer 2008;98(2):282-8.
2008: Berchuck Andrew; Schildkraut Joellen M; Pearce C Leigh; Chenevix-Trench Georgia; Pharoah Paul D
Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium.
Advances in experimental medicine and biology 2008;622():53-67.
2007: Zhang Zhen; Yu Yinhua; Xu Fengji; Berchuck Andrew; van Haaften-Day Carolien; Havrilesky Laura J; de Bruijn Henk W A; van der Zee Ate G J; Woolas Robert P; Jacobs Ian J; Skates Steven; Chan Daniel W; Bast Robert C
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
Gynecologic oncology 2007;107(3):526-31.
2007: Lancaster Johnathan M; Powell C Bethan; Kauff Noah D; Cass Ilana; Chen Lee-May; Lu Karen H; Mutch David G; Berchuck Andrew; Karlan Beth Y; Herzog Thomas J;
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
Gynecologic oncology 2007;107(2):159-62.
2007: Alvarez Secord Angeles; Havrilesky Laura J; Bae-Jump Victoria; Chin Jeanette; Calingaert Brian; Bland Amy; Rutledge Teresa L; Berchuck Andrew; Clarke-Pearson Daniel L; Gehrig Paola A
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Gynecologic oncology 2007;107(2):285-91.
2007: Allard Jay E; Risinger John I; Morrison Carl; Young Gregory; Rose G Scott; Fowler Jeff; Berchuck Andrew; Maxwell G Larry
Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas.
Gynecologic oncology 2007;107(1):52-7.
2007: Berchuck Andrew
Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3552; author reply 3557-8.
2007: Karlan Beth Y; Berchuck Andrew; Mutch David
The role of genetic testing for cancer susceptibility in gynecologic practice.
Obstetrics and gynecology 2007;110(1):155-67.
2007: Secord Angeles Alvarez; Darcy Kathleen M; Hutson Alan; Lee Paula S; Havrilesky Laura J; Grace Lisa A; Berchuck Andrew;
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
Gynecologic oncology 2007;106(1):221-32.
2007: Dainty Louis A; Risinger John I; Morrison Carl; Chandramouli G V R; Bidus Michael A; Zahn Chris; Rose G Scott; Fowler Jeff; Berchuck Andrew; Maxwell G Larry
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.
Gynecologic oncology 2007;105(3):563-70.
2007: Havrilesky Laura J; Secord Angeles Alvarez; Bae-Jump Victoria; Ayeni Tina; Calingaert Brian; Clarke-Pearson Daniel L; Berchuck Andrew; Gehrig Paola A
Outcomes in surgical stage I uterine papillary serous carcinoma.
Gynecologic oncology 2007;105(3):677-82.
2007: Spillman Monique A; Lacy Judith; Murphy Susan K; Whitaker Regina S; Grace Lisa; Teaberry Vanessa; Marks Jeffrey R; Berchuck Andrew
Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.
Gynecologic oncology 2007;105(2):312-20.
2007: Gayther Simon A; Song Honglin; Ramus Susan J; Kjaer Susan Krüger; Whittemore Alice S; Quaye Lydia; Tyrer Jonathan; Shadforth Danielle; Hogdall Estrid; Hogdall Claus; Blaeker Jan; DiCioccio Richard; McGuire Valerie; Webb Penelope M; Beesley Jonathan; Green Adele C; Whiteman David C; Goodman Marc T; Lurie Galina; Carney Michael E; Modugno Francesmary; Ness Roberta B; Edwards Robert P; Moysich Kirsten B; Goode Ellen L; Couch Fergus J; Cunningham Julie M; Sellers Thomas A; Wu Anna H; Pike Malcolm C; Iversen Edwin S; Marks Jeffrey R; Garcia-Closas Montserrat; Brinton Louise; Lissowska Jolanta; Peplonska Beata; Easton Douglas F; Jacobs Ian; Ponder Bruce A J; Schildkraut Joellen; Pearce C Leigh; Chenevix-Trench Georgia; Berchuck Andrew; Pharoah Paul D P;
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.
Cancer research 2007;67(7):3027-35.
2007: Schildkraut Joellen M; Murphy Susan K; Palmieri Rachel T; Iversen Edwin; Moorman Patricia G; Huang Zhiqing; Halabi Susan; Calingaert Brian; Gusberg Alison; Marks Jeffrey R; Berchuck Andrew
Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(3):473-80.
2007: Risinger John Ian; Chandramouli Gadisetti V R; Maxwell G Larry; Custer Mary; Pack Svetlana; Loukinov Dmitri; Aprelikova Olga; Litzi Tracy; Schrump David S; Murphy Susan K; Berchuck Andrew; Lobanenkov Victor; Barrett J Carl
Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1713-9.
2007: Secord Angeles Alvarez; Havrilesky Laura J; Carney Michael E; Soper John T; Clarke-Pearson Daniel L; Rodriguez Gustavo C; Berchuck Andrew
Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
International journal of clinical oncology / Japan Society of Clinical Oncology 2007;12(1):31-6.
2007: Dressman Holly K; Berchuck Andrew; Chan Gina; Zhai Jun; Bild Andrea; Sayer Robyn; Cragun Janiel; Clarke Jennifer; Whitaker Regina S; Li Lihua; Gray Jonathan; Marks Jeffrey; Ginsburg Geoffrey S; Potti Anil; West Mike; Nevins Joseph R; Lancaster Johnathan M
An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):517-25.
2007: Havrilesky Laura J; Cragun Janiel M; Calingaert Brian; Alvarez Secord Angeles; Valea Fidel A; Clarke-Pearson Daniel L; Berchuck Andrew; Soper John T
The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.
Gynecologic oncology 2007;104(2):401-5.
2007: Soper J T; Secord A A; Havrilesky L J; Berchuck A; Clarke-Pearson D L
Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(1):298-303.
2007: Kingsley Chris B; Kuo Wen-Lin; Polikoff Daniel; Berchuck Andy; Gray Joe W; Jain Ajay N
Magellan: a web based system for the integrated analysis of heterogeneous biological data and annotations; application to DNA copy number and expression data in ovarian cancer.
Cancer informatics 2007;2():10-21.
2006: Potti Anil; Dressman Holly K; Bild Andrea; Riedel Richard F; Chan Gina; Sayer Robyn; Cragun Janiel; Cottrill Hope; Kelley Michael J; Petersen Rebecca; Harpole David; Marks Jeffrey; Berchuck Andrew; Ginsburg Geoffrey S; Febbo Phillip; Lancaster Johnathan; Nevins Joseph R
Genomic signatures to guide the use of chemotherapeutics.
Nature medicine 2006;12(11):1294-300.
2006: Maxwell G L; Schildkraut J M; Calingaert B; Risinger J I; Dainty L; Marchbanks P A; Berchuck A; Barrett J C; Rodriguez G C
Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
Gynecologic oncology 2006;103(2):535-40.
2006: Myers Evan R; Havrilesky Laura J; Kulasingam Shalini L; Sanders Gillian D; Cline Kathryn E; Gray Rebecca N; Berchuck Andrew; McCrory Douglas C
Genomic tests for ovarian cancer detection and management.
Evidence report/technology assessment 2006;(145):1-100.
2006: Guillem José G; Wood William C; Moley Jeffrey F; Berchuck Andrew; Karlan Beth Y; Mutch David G; Gagel Robert F; Weitzel Jeffrey; Morrow Monica; Weber Barbara L; Giardiello Francis; Rodriguez-Bigas Miguel A; Church James; Gruber Stephen; Offit Kenneth;
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4642-60.
2006: Guillem José G; Wood William C; Moley Jeffrey F; Berchuck Andrew; Karlan Beth Y; Mutch David G; Gagel Robert F; Weitzel Jeffrey; Morrow Monica; Weber Barbara L; Giardiello Francis; Rodriguez-Bigas Miguel A; Church James; Gruber Stephen; Offit Kenneth
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
Annals of surgical oncology 2006;13(10):1296-321.
2006: Lancaster J M; Dressman H K; Clarke J P; Sayer R A; Martino M A; Cragun J M; Henriott A H; Gray J; Sutphen R; Elahi A; Whitaker R S; West M; Marks J R; Nevins J R; Berchuck A
Identification of genes associated with ovarian cancer metastasis using microarray expression analysis.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(5):1733-45.
2006: Lancaster J M; Sayer R A; Blanchette C; Calingaert B; Konidari I; Gray J; Schildkraut J; Schomberg D W; Marks J R; Berchuck A
High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(4):1529-35.
2006: Lutman Christopher V; Havrilesky Laura J; Cragun Janiel M; Secord Angeles Alvarez; Calingaert Brian; Berchuck Andrew; Clarke-Pearson Daniel L; Soper John T
Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
Gynecologic oncology 2006;102(1):92-7.
2006: Secord Angeles Alvarez; Lee Paula S; Darcy Kathleen M; Havrilesky Laura J; Grace Lisa A; Marks Jeffrey R; Berchuck Andrew
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
Gynecologic oncology 2006;101(3):390-7.
2006: Jewell E; Secord A A; Brotherton T; Berchuck A
Use of trastuzumab in the treatment of metastatic endometrial cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(3):1370-3.
2006: Jones Monica Brown; Houwink Aletta P; Freeman Brandi K; Greenwood Tammy M; Lafky Jacqueline M; Lingle Wilma L; Berchuck Andrew; Maxwell G Lawrence; Podratz Karl C; Maihle Nita J
The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.
Journal of the Society for Gynecologic Investigation 2006;13(4):304-11.
2006: Murphy Susan K; Huang Zhiqing; Wen Yaqing; Spillman Monique A; Whitaker Regina S; Simel Lauren R; Nichols Teresa D; Marks Jeffrey R; Berchuck Andrew
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.
Molecular cancer research : MCR 2006;4(4):283-92.
2006: Jones Ellen; Alvarez Secord Angeles; Prosnitz Leonard R; Samulski Thaddeus V; Oleson James R; Berchuck Andrew; Clarke-Pearson Daniel; Soper John; Dewhirst Mark W; Vujaskovic Zeljko
Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2006;22(2):161-72.
2006: Bidus Michael A; Risinger John I; Chandramouli Gadisetti V R; Dainty Lou A; Litzi Tracy J; Berchuck Andrew; Barrett J Carl; Maxwell G Larry
Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(1):83-8.
2006: Schildkraut Joellen M; Moorman Patricia G; Halabi Susan; Calingaert Brian; Marks Jeffrey R; Berchuck Andrew
Analgesic drug use and risk of ovarian cancer.
Epidemiology (Cambridge, Mass.) 2006;17(1):104-7.
2006: Bild Andrea H; Yao Guang; Chang Jeffrey T; Wang Quanli; Potti Anil; Chasse Dawn; Joshi Mary-Beth; Harpole David; Lancaster Johnathan M; Berchuck Andrew; Olson John A; Marks Jeffrey R; Dressman Holly K; West Mike; Nevins Joseph R
Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
Nature 2006;439(7074):353-7.
2006: Risinger John I; Chandramouli G V R; Maxwell G Larry; Litzi Tracy; Berchuck Andrew; Umar Asad
Gene expression analysis of tumor infiltrating lymphocyte markers in endometrial cancers indicates no significant increases in those cases with microsatellite instability.
Cancer biomarkers : section A of Disease markers 2006;2(1-2):61-8.
2006: Huang Zhiqing; Wen Yaqing; Shandilya Ruby; Marks Jeffrey R; Berchuck Andrew; Murphy Susan K
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer.
Nucleic acids research 2006;34(2):555-63.
2005: Havrilesky Laura J; Cragun Janiel M; Calingaert Brian; Synan Ingrid; Secord Angeles Alvarez; Soper John T; Clarke-Pearson Daniel L; Berchuck Andrew
Resection of lymph node metastases influences survival in stage IIIC endometrial cancer.
Gynecologic oncology 2005;99(3):689-95.
2005: Hoyo Cathrine; Berchuck Andrew; Halabi Susan; Bentley Rex C; Moorman Patricia; Calingaert Brian; Schildkraut Joellen M
Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women.
Cancer causes & control : CCC 2005;16(8):955-63.
2005: Marquez Rebecca T; Baggerly Keith A; Patterson Andrea P; Liu Jinsong; Broaddus Russell; Frumovitz Michael; Atkinson Edward N; Smith David I; Hartmann Lynn; Fishman David; Berchuck Andrew; Whitaker Regina; Gershenson David M; Mills Gordon B; Bast Robert C; Lu Karen H
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6116-26.
2005: Moorman Patricia G; Schildkraut Joellen M; Calingaert Brian; Halabi Susan; Berchuck Andrew
Menopausal hormones and risk of ovarian cancer.
American journal of obstetrics and gynecology 2005;193(1):76-82.
2005: Alvarez Secord A; Jones E L; Hahn C A; Petros W P; Yu D; Havrilesky L J; Soper J T; Berchuck A; Spasojevic I; Clarke-Pearson D L; Prosnitz L R; Dewhirst M W
Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2005;21(4):333-47.
2005: Risinger John I; Maxwell G Larry; Chandramouli Gadisetti V R; Aprelikova Olga; Litzi Tracy; Umar Asad; Berchuck Andrew; Barrett J Carl
Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.
Cancer research 2005;65(12):5031-7.
2005: Maxwell G Larry; Chandramouli G V R; Dainty Lou; Litzi Tracy J; Berchuck Andrew; Barrett J Carl; Risinger John I
Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4056-66.
2005: Kelemen Livia; James Michael; Spurdle Amanda; Campbell Ian; Chang-Claude Jenny; Peel David; Anton-Culver Hoda; Berchuck Andrew; Schildkraut Joellen; Whittemore Alice; McGurie Valerie; DiCioccio Richard A; Duffy David; Chenevix-Trench Georgia
BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
Gynecologic oncology 2005;97(3):807-12.
2005: Cragun Janiel M; Havrilesky Laura J; Calingaert Brian; Synan Ingrid; Secord Angeles Alvarez; Soper John T; Clarke-Pearson Daniel L; Berchuck Andrew
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3668-75.
2005: Berchuck Andrew; Iversen Edwin S; Lancaster Johnathan M; Pittman Jennifer; Luo Jingqin; Lee Paula; Murphy Susan; Dressman Holly K; Febbo Phillip G; West Mike; Nevins Joseph R; Marks Jeffrey R
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3686-96.
2005: Soper J T; Havrilesky L J; Secord A A; Berchuck A; Clarke-Pearson D L
Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(3):542-8.
2005: Soper John T; Secord Angeles Alvarez; Havrilesky Laura J; Berchuck Andrew; Clarke-Pearson Daniel L
Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity.
Gynecologic oncology 2005;97(2):596-601.
2005: Spillman Monique A; Schildkraut Joellen M; Halabi Susan; Moorman Patricia; Calingaert Brian; Bentley Rex C; Marks Jeffrey R; Murphy Susan; Berchuck Andrew
Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.
Gynecologic oncology 2005;97(2):543-9.
2005: Moorman Patricia G; Berchuck Andrew; Calingaert Brian; Halabi Susan; Schildkraut Joellen M
Antidepressant medication use [corrected] and risk of ovarian cancer.
Obstetrics and gynecology 2005;105(4):725-30.
2005: Sayer Robyn A; Lancaster Johnathan M; Pittman Jennifer; Gray Jonathon; Whitaker Regina; Marks Jeffrey R; Berchuck Andrew
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
Gynecologic oncology 2005;96(2):355-61.
2004: Berchuck Andrew; Schildkraut Joellen M; Wenham Robert M; Calingaert Brian; Ali Shazia; Henriott Amy; Halabi Susan; Rodriguez Gustavo C; Gertig Dorota; Purdie David M; Kelemen Livia; Spurdle Amanda B; Marks Jeffrey; Chenevix-Trench Georgia
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004;13(12):2141-7.
2004: Spillman Monique A; Berchuck Andrew
Stretching the surface epithelium.
Journal of the Society for Gynecologic Investigation 2004;11(8):501-2.
2004: Skates Steven J; Horick Nora; Yu Yinhua; Xu Feng-Ji; Berchuck Andrew; Havrilesky Laura J; de Bruijn Henk W A; van der Zee Ate G J; Woolas Robert P; Jacobs Ian J; Zhang Zhen; Bast Robert C
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(20):4059-66.
2004: Zhang Zhen; Bast Robert C; Yu Yinhua; Li Jinong; Sokoll Lori J; Rai Alex J; Rosenzweig Jason M; Cameron Bonnie; Wang Young Y; Meng Xiao-Ying; Berchuck Andrew; Van Haaften-Day Carolien; Hacker Neville F; de Bruijn Henk W A; van der Zee Ate G J; Jacobs Ian J; Fung Eric T; Chan Daniel W
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
Cancer research 2004;64(16):5882-90.
2004: Alvarez Secord Angeles; Sayer Robyn; Snyder Stacey A; Broadwater Gloria; Rodriguez Gustavo C; Berchuck Andrew; Blackwell Kimberly
The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
Gynecologic oncology 2004;94(1):74-9.
2004: Lu Karen H; Patterson Andrea P; Wang Lin; Marquez Rebecca T; Atkinson Edward N; Baggerly Keith A; Ramoth Lance R; Rosen Daniel G; Liu Jinsong; Hellstrom Ingegerd; Smith David; Hartmann Lynn; Fishman David; Berchuck Andrew; Schmandt Rosemarie; Whitaker Regina; Gershenson David M; Mills Gordon B; Bast Robert C
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3291-300.
2004: Rendi Mara H; Suh Nanjoo; Lamph William W; Krajewski Stan; Reed John C; Heyman Richard A; Berchuck Andrew; Liby Karen; Risingsong Renee; Royce Darlene B; Williams Charlotte R; Sporn Michael B
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
Cancer research 2004;64(10):3566-71.
2004: Berchuck Andrew; Iversen Edwin S; Lancaster Johnathan M; Dressman Holly K; West Mike; Nevins Joseph R; Marks Jeffrey R
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
American journal of obstetrics and gynecology 2004;190(4):910-25.
2004: Lancaster Johnathan M; Dressman Holly K; Whitaker Regina S; Havrilesky Laura; Gray Jonathan; Marks Jeffrey R; Nevins Joseph R; Berchuck Andrew
Gene expression patterns that characterize advanced stage serous ovarian cancers.
Journal of the Society for Gynecologic Investigation 2004;11(1):51-9.
2003: Wenham Robert M; Schildkraut Joellen M; McLean Kia; Calingaert Brian; Bentley Rex C; Marks Jeffrey; Berchuck Andrew
Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4396-403.
2003: Havrilesky Laura; Darcy kathleen M; Hamdan Hasnah; Priore Roger L; Leon Jorge; Bell Jeffrey; Berchuck Andrew;
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(20):3814-25.
2003: Tanyi Janos L; Hasegawa Yutaka; Lapushin Ruth; Morris Andrew J; Wolf Judith K; Berchuck Andrew; Lu Karen; Smith David I; Kalli Kimberly; Hartmann Lynn C; McCune Karen; Fishman David; Broaddus Russell; Cheng Kwai W; Atkinson Edward N; Yamal Jose M; Bast Robert C; Felix Edward A; Newman Robert A; Mills Gordon B
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3534-45.
2003: Wenham Robert M; Calingaert Brian; Ali Shazia; McClean Kia; Whitaker Regina; Bentley Rex; Lancaster Johnathan M; Schildkraut Joellen; Marks Jeffrey; Berchuck Andrew
Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer.
Journal of the Society for Gynecologic Investigation 2003;10(6):381-7.
2003: Havrilesky Laura J; Peterson Bercedis L; Dryden Damla K; Soper John T; Clarke-Pearson Daniel L; Berchuck Andrew
Predictors of clinical outcomes in the laparoscopic management of adnexal masses.
Obstetrics and gynecology 2003;102(2):243-51.
2003: Jones Ellen L; Samulski Thaddeus V; Dewhirst Mark W; Alvarez-Secord Angeles; Berchuck Andrew; Clarke-Pearson Daniel; Havrilesky Laura J; Soper John; Prosnitz Leonard R
A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma.
Cancer 2003;98(2):277-82.
2003: Havrilesky Laura J; Wong Terence Z; Secord Angeles Alvarez; Berchuck Andrew; Clarke-Pearson Daniel L; Jones Ellen L
The role of PET scanning in the detection of recurrent cervical cancer.
Gynecologic oncology 2003;90(1):186-90.
2003: Vine Marilyn F; Calingaert Brian; Berchuck Andrew; Schildkraut Joellen M
Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.
Gynecologic oncology 2003;90(1):75-82.
2003: Risinger John I; Maxwell G Larry; Berchuck Andrew; Barrett J Carl
Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers.
Annals of the New York Academy of Sciences 2003;983():208-12.
2003: van den Brûle Frédéric; Califice Stéphane; Garnier Frédérique; Fernandez Pedro L; Berchuck Andrew; Castronovo Vincent
Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin.
Laboratory investigation; a journal of technical methods and pathology 2003;83(3):377-86.
2003: Lancaster Johnathan M; Wenham Robert M; Halabi Susan; Calingaert Brian; Marks Jeffrey R; Moorman Patricia G; Bentley Rex C; Berchuck Andrew; Schildkraut Joellen M
No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2003;12(3):226-7.
2003: Lancaster Johnathan M; Sayer Robyn; Blanchette Carrie; Calingaert Brian; Whitaker Regina; Schildkraut Joellen; Marks Jeffrey; Berchuck Andrew
High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):762-6.
2003: Gray Joe W; Suzuki Seiji; Kuo Wen-Lin; Polikoff Daniel; Deavers Michael; Smith-McCune Karen; Berchuck Andrew; Pinkel Dan; Albertson Donna; Mills Gordon B
Specific keynote: genome copy number abnormalities in ovarian cancer.
Gynecologic oncology 2003;88(1 Pt 2):S16-21; discussion S22-4.
2003: Risinger John I; Maxwell G Larry; Chandramouli G V R; Jazaeri Amir; Aprelikova Olga; Patterson Tricia; Berchuck Andrew; Barrett J Carl
Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.
Cancer research 2003;63(1):6-11.
2003: Havrilesky Laura J; Alvarez Angeles A; Sayer Robyn A; Lancaster Johnathan M; Soper John T; Berchuck Andrew; Clarke-Pearson Daniel L; Rodriguez Gustavo C; Carney Michael E
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
Gynecologic oncology 2003;88(1):51-7.
2002: Moorman Patricia G; Schildkraut Joellen M; Calingaert Brian; Halabi Susan; Vine Marilyn F; Berchuck Andrew
Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).
Cancer causes & control : CCC 2002;13(9):807-11.
2002: Wenham Robert M; Lancaster Johnathan M; Berchuck Andrew
Molecular aspects of ovarian cancer.
Best practice & research. Clinical obstetrics & gynaecology 2002;16(4):483-97.
2002: Dixon Darlene; Flake Gordon P; Moore Alicia B; He Hong; Haseman Joseph K; Risinger John I; Lancaster Johnathan M; Berchuck Andrew; Barrett J Carl; Robboy Stanley J
Cell proliferation and apoptosis in human uterine leiomyomas and myometria.
Virchows Archiv : an international journal of pathology 2002;441(1):53-62.
2002: Rodriguez Gustavo C; Nagarsheth Nimesh P; Lee Karen L; Bentley Rex C; Walmer David K; Cline Mark; Whitaker Regina S; Isner Pam; Berchuck Andrew; Dodge Richard K; Hughes Claude L
Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta.
Journal of the National Cancer Institute 2002;94(1):50-60.
2001: van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky L J; de Bruijn H W; van der Zee A G; Bast R C; Hacker N F
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
Cancer 2001;92(11):2837-44.
2001: Havrilesky L J; Alvarez A A; Whitaker R S; Marks J R; Berchuck A
Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Gynecologic oncology 2001;83(3):491-500.
2001: Vine M F; Ness R B; Calingaert B; Schildkraut J M; Berchuck A
Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.
Gynecologic oncology 2001;83(3):466-71.
2001: Stout J E; Woods C W; Alvarez A A; Berchuck A; Dukes Hamilton C
Mycobacterium bovis peritonitis mimicking ovarian cancer in a young woman.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(4):E14-6.
2001: Alvarez A A; Lambers A R; Lancaster J M; Maxwell G L; Ali S; Gumbs C; Berchuck A; Futreal P A
Allele loss on chromosome 1p36 in epithelial ovarian cancers.
Gynecologic oncology 2001;82(1):94-8.
2001: Lancaster J M; Risinger J I; Carney M E; Barrett J C; Berchuck A
Mutational analysis of the PTEN gene in human uterine sarcomas.
American journal of obstetrics and gynecology 2001;184(6):1051-3.
2001: Havrilesky L J; McMahon C P; Lobenhofer E K; Whitaker R; Marks J R; Berchuck A
Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
Journal of the Society for Gynecologic Investigation 2001;8(2):104-13.
2001: Maxwell G L; Risinger J I; Alvarez A A; Barrett J C; Berchuck A
Favorable survival associated with microsatellite instability in endometrioid endometrial cancers.
Obstetrics and gynecology 2001;97(3):417-22.
2001: Alvarez A A; Moore W F; Robboy S J; Bentley R C; Gumbs C; Futreal P A; Berchuck A
K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.
Gynecologic oncology 2001;80(2):201-6.
2000: Suzuki S; Moore D H; Ginzinger D G; Godfrey T E; Barclay J; Powell B; Pinkel D; Zaloudek C; Lu K; Mills G; Berchuck A; Gray J W
An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer.
Cancer research 2000;60(19):5382-5.
2000: Maxwell G L; Risinger J I; Hayes K A; Alvarez A A; Dodge R K; Barrett J C; Berchuck A
Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):2999-3005.
2000: Peng H; Xu F; Pershad R; Hunt K K; Frazier M L; Berchuck A; Gray J W; Hogg D; Bast R C; Yu Y
ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers.
International journal of cancer. Journal international du cancer 2000;86(5):690-4.
2000: Moore W F; Bentley R C; Berchuck A; Robboy S J
Some mullerian inclusion cysts in lymph nodes may sometimes be metastases from serous borderline tumors of the ovary.
The American journal of surgical pathology 2000;24(5):710-8.
2000: Schildkraut J M; Halabi S; Bastos E; Marchbanks P A; McDonald J A; Berchuck A
Prognostic factors in early-onset epithelial ovarian cancer: a population-based study.
Obstetrics and gynecology 2000;95(1):119-27.
2000: Ahmed M N; Kim K; Haddad B; Berchuck A; Qumsiyeh M B
Comparative genomic hybridization studies in hydatidiform moles and choriocarcinoma: amplification of 7q21-q31 and loss of 8p12-p21 in choriocarcinoma.
Cancer genetics and cytogenetics 2000;116(1):10-5.
2000: Bösze P; Bast R C; Berchuck A; Burke H B; Buller R E; Creasman W T; Dubeau L; Fox H; Geisler H E; Geisler J P; Henson D E; Rustin G J; Vermorken J B; Wells M; Wilbanks G D
Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO.
European journal of gynaecological oncology 2000;21(5):513-26.
1999: Berchuck A; Schildkraut J M; Marks J R; Futreal P A
Managing hereditary ovarian cancer risk.
Cancer 1999;86(11 Suppl):2517-24.
1999: Ashih H; Gustilo-Ashby T; Myers E R; Andrews J; Clarke-Pearson D L; Berry D; Berchuck A
Cost-effectiveness of treatment of early stage endometrial cancer.
Gynecologic oncology 1999;74(2):208-16.
1999: Lambers A R; Gumbs C; Ali S; Marks J R; Iglehart J D; Berchuck A; Futreal P A
Bcl10 is not a target for frequent mutation in human carcinomas.
British journal of cancer 1999;80(10):1575-6.
1999: Brown M R; Chuaqui R; Vocke C D; Berchuck A; Middleton L P; Emmert-Buck M R; Kohn E C
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
Gynecologic oncology 1999;74(1):98-102.
1999: Zweemer R P; Shaw P A; Verheijen R M; Ryan A; Berchuck A; Ponder B A; Risch H; McLaughlin J R; Narod S A; Menko F H; Kenemans P; Jacobs I J
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Journal of clinical pathology 1999;52(5):372-5.
1999: Zhang Z; Barnhill S D; Zhang H; Xu F; Yu Y; Jacobs I; Woolas R P; Berchuck A; Madyastha K R; Bast R C
Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
Gynecologic oncology 1999;73(1):56-61.
1999: Berchuck A; Carney M E; Futreal P A
Genetic susceptibility testing and prophylactic oophorectomy.
European journal of obstetrics, gynecology, and reproductive biology 1999;82(2):159-64.
1998: van der Heijden O; Chiu H C; Park T C; Takahashi H; LiVolsi V A; Risinger J I; Barrett J C; Berchuck A; Evans A C; Behbakht K; Menzin A W; Liu P C; Benjamin I; Morgan M A; King S A; Rubin S C; Boyd J
Allelotype analysis of uterine leiomyoma: localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q.
Molecular carcinogenesis 1998;23(4):243-7.
1998: Risinger J I; Hayes K; Maxwell G L; Carney M E; Dodge R K; Barrett J C; Berchuck A
PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(12):3005-10.
1998: Berchuck A; Heron K A; Carney M E; Lancaster J M; Fraser E G; Vinson V L; Deffenbaugh A M; Miron A; Marks J R; Futreal P A; Frank T S
Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2433-7.
1998: Carney M E; Maxwell G L; Lancaster J M; Gumbs C; Marks J; Berchuck A; Futreal P A
Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers.
Journal of the Society for Gynecologic Investigation 1998;5(5):281-5.
1998: Bast R C; Pusztai L; Kerns B J; MacDonald J A; Jordan P; Daly L; Boyer C M; Mendelsohn J; Berchuck A
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues.
Hybridoma 1998;17(4):313-21.
1998: Boente M P; Berchuck A; Whitaker R S; Kalén A; Xu F J; Clarke-Pearson D L; Bell R M; Bast R C
Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines.
Gynecologic oncology 1998;70(1):49-55.
1998: Maxwell G L; Risinger J I; Tong B; Shaw H; Barrett J C; Berchuck A; Futreal P A
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Gynecologic oncology 1998;70(1):13-6.
1998: Lancaster J M; Berchuck A; Carney M E; Wiseman R; Taylor J A
Progesterone receptor gene polymorphism and risk for breast and ovarian cancer.
British journal of cancer 1998;78(2):277.
1998: Maxwell G L; Risinger J I; Gumbs C; Shaw H; Bentley R C; Barrett J C; Berchuck A; Futreal P A
Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.
Cancer research 1998;58(12):2500-3.
1998: Berchuck A; Carney M; Lancaster J M; Marks J; Futreal A P
Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.
Clinical obstetrics and gynecology 1998;41(1):157-66.
1997: Layfield L J; Saria E A; Berchuck A; Dodge R K; Thompson J K; Conlon D H; Kerns B J
Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis.
Journal of surgical oncology 1997;66(4):230-6; discussion 236-7.
1997: Berchuck A; Schildkraut J
Oral contraceptive pills. Prevention of ovarian cancer and other benefits.
North Carolina medical journal 1997;58(6):404-7; discussion 408.
1997: Choi C; Cho S; Horikawa I; Berchuck A; Wang N; Cedrone E; Jhung S W; Lee J B; Kerr J; Chenevix-Trench G; Kim S; Barrett J C; Koi M
Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.
Genes, chromosomes & cancer 1997;20(3):234-42.
1997: Risinger J I; Hayes A K; Berchuck A; Barrett J C
PTEN/MMAC1 mutations in endometrial cancers.
Cancer research 1997;57(21):4736-8.
1997: Berchuck A; Carney M
Human ovarian cancer of the surface epithelium.
Biochemical pharmacology 1997;54(5):541-4.
1997: Packenham J P; du Manoir S; Schrock E; Risinger J I; Dixon D; Denz D N; Evans J A; Berchuck A; Barrett J C; Devereux T R; Ried T
Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization.
Molecular carcinogenesis 1997;19(4):273-9.
1997: Lancaster J M; Berchuck A; Futreal P A; Wiseman R W
Dideoxy fingerprinting assay for BRCA1 mutation analysis.
Molecular carcinogenesis 1997;19(3):176-9.
1997: Schildkraut J M; Bastos E; Berchuck A
Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.
Journal of the National Cancer Institute 1997;89(13):932-8.
1997: Clifford S L; Kaminetsky C P; Cirisano F D; Dodge R; Soper J T; Clarke-Pearson D L; Berchuck A
Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer.
American journal of obstetrics and gynecology 1997;176(6):S229-32.
1997: Mooney E E; Robboy S J; Hammond C B; Berchuck A; Bentley R C
Signet-ring cell carcinoma of the endometrium: a primary tumor masquerading as a metastasis.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1997;16(2):169-72.
1997: Berchuck A
Endometrial carcinoma and its precursors.
Current therapy in endocrinology and metabolism 1997;6():599-602.
1996: Lancaster J M; Brownlee H A; Bell D A; Futreal P A; Marks J R; Berchuck A; Wiseman R W; Taylor J A
Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer.
Molecular carcinogenesis 1996;17(3):160-2.
1996: Kohler M F; Carney P; Dodge R; Soper J T; Clarke-Pearson D L; Marks J R; Berchuck A
p53 overexpression in advanced-stage endometrial adenocarcinoma.
American journal of obstetrics and gynecology 1996;175(5):1246-52.
1996: van den Brule F A; Buicu C; Berchuck A; Bast R C; Deprez M; Liu F T; Cooper D N; Pieters C; Sobel M E; Castronovo V
Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma.
Human pathology 1996;27(11):1185-91.
1996: Rubin S C; Benjamin I; Behbakht K; Takahashi H; Morgan M A; LiVolsi V A; Berchuck A; Muto M G; Garber J E; Weber B L; Lynch H T; Boyd J
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
The New England journal of medicine 1996;335(19):1413-6.
1996: Vaughn J P; Cirisano F D; Huper G; Berchuck A; Futreal P A; Marks J R; Iglehart J D
Cell cycle control of BRCA2.
Cancer research 1996;56(20):4590-4.
1996: Elbendary A A; Cirisano F D; Evans A C; Davis P L; Iglehart J D; Marks J R; Berchuck A
Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(9):1571-5.
1996: Berchuck A; Cirisano F; Lancaster J M; Schildkraut J M; Wiseman R W; Futreal A; Marks J R
Role of BRCA1 mutation screening in the management of familial ovarian cancer.
American journal of obstetrics and gynecology 1996;175(3 Pt 1):738-46.
1996: Risinger J I; Umar A; Boyd J; Berchuck A; Kunkel T A; Barrett J C
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair.
Nature genetics 1996;14(1):102-5.
1996: Terry L A; Boyd J; Alcorta D; Lyon T; Solomon G; Hannon G; Berchuck A; Beach D; Barrett J C
Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines.
Molecular carcinogenesis 1996;16(4):221-8.
1996: Vaughn J P; Davis P L; Jarboe M D; Huper G; Evans A C; Wiseman R W; Berchuck A; Iglehart J D; Futreal P A; Marks J R
BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(6):711-5.
1996: Lancaster J M; Wooster R; Mangion J; Phelan C M; Cochran C; Gumbs C; Seal S; Barfoot R; Collins N; Bignell G; Patel S; Hamoudi R; Larsson C; Wiseman R W; Berchuck A; Iglehart J D; Marks J R; Ashworth A; Stratton M R; Futreal P A
BRCA2 mutations in primary breast and ovarian cancers.
Nature genetics 1996;13(2):238-40.
1996: Olt G; Soper J; Ramakrishnan S; Xu F; Berchuck A; Clarke-Pearson D; Dodge R; Bast R C
Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer.
American journal of obstetrics and gynecology 1996;174(4):1316-9.
1996: Lancaster J M; Cochran C J; Brownlee H A; Evans A C; Berchuck A; Futreal P A; Wiseman R W
Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test.
Journal of the National Cancer Institute 1996;88(8):552-4.
1996: Boente M P; Hamilton T C; Godwin A K; Buetow K; Kohler M F; Hogan W M; Berchuck A; Young R C
Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment.
Current problems in cancer 1996;20(2):83-137.
1996: Lancaster J M; Wiseman R W; Berchuck A
An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.
Obstetrics and gynecology 1996;87(2):306-9.
1996: Berchuck A; Kohler M F; Bast R C
Molecular genetic features of ovarian cancer.
Progress in clinical and biological research 1996;394():269-84.
1996: Hussein A M; Petros W P; Ross M; Vredenburgh J J; Affrontil M L; Jones R B; Shpall E J; Rubin P; Elkordy M; Gilbert C; Gupton C; Egorin M J; Soper J; Berchuck A; Clarke-Person D; Berry D A; Peters W P
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 1996;37(6):561-8.
1995: Risinger J I; Umar A; Boyer J C; Evans A C; Berchuck A; Kunkel T A; Barrett J C
Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity.
Cancer research 1995;55(23):5664-9.
1995: Hurteau J A; Woolas R P; Jacobs I J; Oram D C; Kurman C C; Rubin L A; Nelson D L; Berchuck A; Bast R C; Mills G B
Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Cancer 1995;76(9):1615-20.
1995: Berchuck A; Boyd J
Molecular basis of endometrial cancer.
Cancer 1995;76(10 Suppl):2034-40.
1995: Evans A C; Soper J T; Clarke-Pearson D L; Berchuck A; Rodriguez G C; Hammond C B
Gestational trophoblastic disease metastatic to the central nervous system.
Gynecologic oncology 1995;59(2):226-30.
1995: Berchuck A; Bast R C
p53-based gene therapy of ovarian cancer: magic bullet?
Gynecologic oncology 1995;59(2):169-70.
1995: Liu J R; Conaway M; Rodriguez G C; Soper J T; Clarke-Pearson D L; Berchuck A
Relationship between race and interval to treatment in endometrial cancer.
Obstetrics and gynecology 1995;86(4 Pt 1):486-90.
1995: Berchuck A; Anspach C; Evans A C; Soper J T; Rodriguez G C; Dodge R; Robboy S; Clarke-Pearson D L
Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma.
Gynecologic oncology 1995;59(1):20-4.
1995: Woolas R P; Conaway M R; Xu F; Jacobs I J; Yu Y; Daly L; Davies A P; O'Briant K; Berchuck A; Soper J T
Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses.
Gynecologic oncology 1995;59(1):111-6.
1995: Kohler M F; Berkholz A; Risinger J I; Elbendary A; Boyd J; Berchuck A
Mutational analysis of the estrogen-receptor gene in endometrial carcinoma.
Obstetrics and gynecology 1995;86(1):33-7.
1995: Havrilesky L J; Elbendary A; Hurteau J A; Whitaker R S; Rodriguez G C; Berchuck A
Chemotherapy-induced apoptosis in epithelial ovarian cancers.
Obstetrics and gynecology 1995;85(6):1007-10.
1995: Schildkraut J M; Collins N K; Dent G A; Tucker J A; Barrett J C; Berchuck A; Boyd J
Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.
American journal of obstetrics and gynecology 1995;172(3):908-13.
1995: Lessey B A; Albelda S; Buck C A; Castelbaum A J; Yeh I; Kohler M; Berchuck A
Distribution of integrin cell adhesion molecules in endometrial cancer.
The American journal of pathology 1995;146(3):717-26.
1995: Soper J T; Evans A C; Rodriguez G; Berchuck A; Clarke-Pearson D L; Hammond C B
Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease.
Gynecologic oncology 1995;56(3):421-4.
1995: Soper J T; Rodriguez G; Berchuck A; Clarke-Pearson D L
Long and short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery: comparison of flap-specific complications.
Gynecologic oncology 1995;56(2):271-5.
1995: Havrilesky L J; Hurteau J A; Whitaker R S; Elbendary A; Wu S; Rodriguez G C; Bast R C; Berchuck A
Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.
Cancer research 1995;55(4):944-8.
1995: Berchuck A
Biomarkers in the ovary.
Journal of cellular biochemistry. Supplement 1995;23():223-6.
1995: Bast R C; Boyer C M; Xu F J; Wiener J; Dabel R; Woolas R; Jacobs I; Berchuck A
Molecular approaches to prevention and detection of epithelial ovarian cancer.
Journal of cellular biochemistry. Supplement 1995;23():219-22.
1995: Berchuck A
Biomarkers in the endometrium.
Journal of cellular biochemistry. Supplement 1995;23():174-8.
1994: Soper J T; Evans A C; Conaway M R; Clarke-Pearson D L; Berchuck A; Hammond C B
Evaluation of prognostic factors and staging in gestational trophoblastic tumor.
Obstetrics and gynecology 1994;84(6):969-73.
1994: Elbendary A; Berchuck A; Davis P; Havrilesky L; Bast R C; Iglehart J D; Marks J R
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994;5(12):1301-7.
1994: Rodriguez G C; Hughes C L; Soper J T; Berchuck A; Clarke-Pearson D L; Hammond C B
Serum progesterone for the exclusion of early pregnancy in women at risk for recurrent gestational trophoblastic neoplasia.
Obstetrics and gynecology 1994;84(5):794-7.
1994: Berchuck A; Elbendary A; Havrilesky L; Rodriguez G C; Bast R C
Pathogenesis of ovarian cancers.
Journal of the Society for Gynecologic Investigation 1994;1(3):181-90.
1994: Soper J T; Clarke-Pearson D L; Berchuck A; Rodriguez G; Hammond C B
5-day methotrexate for women with metastatic gestational trophoblastic disease.
Gynecologic oncology 1994;54(1):76-9.
1994: Hurteau J; Rodriguez G C; Whitaker R S; Shah S; Mills G; Bast R C; Berchuck A
Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites.
Cancer 1994;74(1):93-9.
1994: Risinger J I; Berchuck A; Kohler M F; Boyd J
Mutations of the E-cadherin gene in human gynecologic cancers.
Nature genetics 1994;7(1):98-102.
1994: Lukes A S; Kohler M F; Pieper C F; Kerns B J; Bentley R; Rodriguez G C; Soper J T; Clarke-Pearson D L; Bast R C; Berchuck A
Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
Cancer 1994;73(9):2380-5.
1994: Wu S; Meeker W A; Wiener J R; Berchuck A; Bast R C; Boyer C M
Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha.
Gynecologic oncology 1994;53(1):59-63.
1994: Wiener J R; Hurteau J A; Kerns B J; Whitaker R S; Conaway M R; Berchuck A; Bast R C
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.
American journal of obstetrics and gynecology 1994;170(4):1177-83.
1994: Xu F J; Yu Y H; Daly L; Anselmino L; Hass G M; Berchuck A; Rodriguez G C; Soper J T; Clarke-Pearson D L; Hollis D
OVX1 as a marker for early stage endometrial carcinoma.
Cancer 1994;73(7):1855-8.
1994: Rodriguez G C; Clarke-Pearson D L; Soper J T; Berchuck A; Synan I; Dodge R K
The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer.
Obstetrics and gynecology 1994;83(3):445-8.
1994: Myers E R; Clarke-Pearson D L; Olt G J; Soper J T; Berchuck A
Preoperative coagulation testing on a gynecologic oncology service.
Obstetrics and gynecology 1994;83(3):438-44.
1994: Wiener J R; Kerns B J; Harvey E L; Conaway M R; Iglehart J D; Berchuck A; Bast R C
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression.
Journal of the National Cancer Institute 1994;86(5):372-8.
1994: Kerns B J; Jordan P A; Faerman L L; Berchuck A; Bast R C; Layfield L J
Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis.
American journal of clinical pathology 1994;101(2):192-7.
1994: Berchuck A; Kohler M F; Hopkins M P; Humphrey P A; Robboy S J; Rodriguez G C; Soper J T; Clarke-Pearson D L; Bast R C
Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
Gynecologic oncology 1994;52(2):232-6.
1994: Berchuck A; Kohler M F; Marks J R; Wiseman R; Boyd J; Bast R C
The p53 tumor suppressor gene frequently is altered in gynecologic cancers.
American journal of obstetrics and gynecology 1994;170(1 Pt 1):246-52.
1994: Liu F S; Kohler M F; Marks J R; Bast R C; Boyd J; Berchuck A
Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
Obstetrics and gynecology 1994;83(1):118-24.
1994: Soper J T; Evans A C; Clarke-Pearson D L; Berchuck A; Rodriguez G; Hammond C B
Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
Obstetrics and gynecology 1994;83(1):113-7.
1994: Bast R C; Xu F; Yu Y; Crews J; Argon Y; Maier L; Lidor Y; Berchuck A; Boyer C M
Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer.
Immunology series 1994;61():23-30.
1994: van den Brûle F A; Berchuck A; Bast R C; Liu F T; Gillet C; Sobel M E; Castronovo V
Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1096-9.
1993: Berchuck A; Dodge R K
Interval to treatment in endometrial cancer.
American journal of obstetrics and gynecology 1993;169(6):1655-6.
1993: Leopold K A; Oleson J R; Clarke-Pearson D; Soper J; Berchuck A; Samulski T V; Page R L; Blivin J; Tomberlin J K; Dewhirst M W
Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma.
International journal of radiation oncology, biology, physics 1993;27(5):1245-51.
1993: Soisson A P; Olt G; Soper J T; Berchuck A; Rodriguez G; Clarke-Pearson D L
Prevention of superficial wound separation with subcutaneous retention sutures.
Gynecologic oncology 1993;51(3):330-4.
1993: Woolas R P; Xu F J; Jacobs I J; Yu Y H; Daly L; Berchuck A; Soper J T; Clarke-Pearson D L; Oram D H; Bast R C
Elevation of multiple serum markers in patients with stage I ovarian cancer.
Journal of the National Cancer Institute 1993;85(21):1748-51.
1993: Risinger J I; Berchuck A; Kohler M F; Watson P; Lynch H T; Boyd J
Genetic instability of microsatellites in endometrial carcinoma.
Cancer research 1993;53(21):5100-3.
1993: Kohler M F; Nishii H; Humphrey P A; Saski H; Marks J; Bast R C; Clarke-Pearson D L; Boyd J; Berchuck A
Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias.
American journal of obstetrics and gynecology 1993;169(3):690-4.
1993: Kohler M F; Marks J R; Wiseman R W; Jacobs I J; Davidoff A M; Clarke-Pearson D L; Soper J T; Bast R C; Berchuck A
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer.
Journal of the National Cancer Institute 1993;85(18):1513-9.
1993: Boente M P; Hurteau J; Rodriguez G C; Bast R C; Berchuck A
The biology of ovarian cancer.
Current opinion in oncology 1993;5(5):900-7.
1993: Lidor Y J; Xu F J; Martínez-Maza O; Olt G J; Marks J R; Berchuck A; Ramakrishnan S; Berek J S; Bast R C
Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells.
Experimental cell research 1993;207(2):332-9.
1993: Xu F J; Yu Y H; Daly L; DeSombre K; Anselmino L; Hass G M; Berchuck A; Soper J T; Clarke-Pearson D L; Boyer C
OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1506-10.
1993: Jordan P A; Kerns B J; Pence J C; Kohler M F; Bast R C; Kinney R B; Berchuck A
Determination of proliferation index in advanced ovarian cancer using quantitative image analysis.
American journal of clinical pathology 1993;99(6):736-40.
1993: McKenzie S J; DeSombre K A; Bast B S; Hollis D R; Whitaker R S; Berchuck A; Boyer C M; Bast R C
Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
Cancer 1993;71(12):3942-6.
1993: Kohler M F; Kerns B J; Humphrey P A; Marks J R; Bast R C; Berchuck A
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Obstetrics and gynecology 1993;81(5 ( Pt 1)):643-50.
1993: Clarke-Pearson D L; Synan I S; Dodge R; Soper J T; Berchuck A; Coleman R E
A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery.
American journal of obstetrics and gynecology 1993;168(4):1146-53; discussion 1153-4.
1993: Sasaki H; Nishii H; Takahashi H; Tada A; Furusato M; Terashima Y; Siegal G P; Parker S L; Kohler M F; Berchuck A
Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma.
Cancer research 1993;53(8):1906-10.
1993: Wu S; Boyer C M; Whitaker R S; Berchuck A; Wiener J R; Weinberg J B; Bast R C
Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.
Cancer research 1993;53(8):1939-44.
1993: Jacobs I J; Smith S A; Wiseman R W; Futreal P A; Harrington T; Osborne R J; Leech V; Molyneux A; Berchuck A; Ponder B A
A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus.
Cancer research 1993;53(6):1218-21.
1993: Bast R C; Boyer C M; Jacobs I; Xu F J; Wu S; Wiener J; Kohler M; Berchuck A
Cell growth regulation in epithelial ovarian cancer.
Cancer 1993;71(4 Suppl):1597-601.
1993: Xu F; Lupu R; Rodriguez G C; Whitaker R S; Boente M P; Berchuck A; Yu Y; DeSombre K A; Boyer C M; Bast R C
Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
International journal of cancer. Journal international du cancer 1993;53(3):401-8.
1993: Berchuck A; Kohler M F; Boente M P; Rodriguez G C; Whitaker R S; Bast R C
Growth regulation and transformation of ovarian epithelium.
Cancer 1993;71(2 Suppl):545-51.
1993: Rodríguez G C; Boente M P; Berchuck A; Whitaker R S; O'Briant K C; Xu F; Bast R C
The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines.
American journal of obstetrics and gynecology 1993;168(1 Pt 1):228-32.
1992: Soisson A P; Soper J T; Berchuck A; Dodge R; Clarke-Pearson D
Radical hysterectomy in obese women.
Obstetrics and gynecology 1992;80(6):940-3.
1992: Jacobs I J; Kohler M F; Wiseman R W; Marks J R; Whitaker R; Kerns B A; Humphrey P; Berchuck A; Ponder B A; Bast R C
Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.
Journal of the National Cancer Institute 1992;84(23):1793-8.
1992: Boente M P; Berchuck A; Rodriguez G C; Davidoff A; Whitaker R; Xu F J; Marks J; Clarke-Pearson D L; Bast R C
The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells.
American journal of obstetrics and gynecology 1992;167(6):1877-82.
1992: Soper J T; Johnson P; Johnson V; Berchuck A; Clarke-Pearson D L
Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma.
Obstetrics and gynecology 1992;80(6):949-53.
1992: Wiener J R; Berchuck A; Bast R C
Biology and therapy with biologic agents in gynecologic cancer.
Current opinion in oncology 1992;4(5):946-54.
1992: Olt G; Berchuck A; Soisson A P; Boyer C M; Bast R C
Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer.
Cancer 1992;70(8):2137-42.
1992: Rodriguez G C; Soper J T; Berchuck A; Oleson J; Dodge R; Montana G; Clarke-Pearson D L
Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(10):1553-60.
1992: Berchuck A; Kohler M F; Bast R C
Oncogenes in ovarian cancer.
Hematology/oncology clinics of North America 1992;6(4):813-27.
1992: Kerns B J; Jordan P A; Moore M B; Humphrey P A; Berchuck A; Kohler M F; Bast R C; Iglehart J D; Marks J R
p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1992;40(7):1047-51.
1992: Ignar-Trowbridge D; Risinger J I; Dent G A; Kohler M; Berchuck A; McLachlan J A; Boyd J
Mutations of the Ki-ras oncogene in endometrial carcinoma.
American journal of obstetrics and gynecology 1992;167(1):227-32.
1992: Soper J T; Berchuck A; Dodge R; Clarke-Pearson D L
Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging.
Obstetrics and gynecology 1992;79(6):993-7.
1992: O'Briant K; Chrysson N; Hunter V; Tyson F; Tanner M; Daly L; George S L; Berchuck A; Soper J; Fowler W
Ha-ras polymorphisms in epithelial ovarian cancer.
Gynecologic oncology 1992;45(3):299-302.
1992: Bast R C; Jacobs I; Berchuck A
Malignant transformation of ovarian epithelium.
Journal of the National Cancer Institute 1992;84(8):556-8.
1992: Berchuck A; Boente M P; Bast R C
The use of tumor markers in the management of patients with gynecologic carcinomas.
Clinical obstetrics and gynecology 1992;35(1):45-54.
1992: Kohler M F; Berchuck A; Davidoff A M; Humphrey P A; Dodge R K; Iglehart J D; Soper J T; Clarke-Pearson D L; Bast R C; Marks J R
Overexpression and mutation of p53 in endometrial carcinoma.
Cancer research 1992;52(6):1622-7.
1992: Berchuck A; Rodriguez G; Olt G; Whitaker R; Boente M P; Arrick B A; Clarke-Pearson D L; Bast R C
Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.
American journal of obstetrics and gynecology 1992;166(2):676-84.
1992: Berchuck A; Boente M P; Kerns B J; Kinney R B; Soper J T; Clarke-Pearson D L; Bast R C; Bacus S S
Ploidy analysis of epithelial ovarian cancers using image cytometry.
Gynecologic oncology 1992;44(1):61-5.
1991: Xu F J; Ramakrishnan S; Daly L; Soper J T; Berchuck A; Clarke-Pearson D; Bast R C
Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.
American journal of obstetrics and gynecology 1991;165(5 Pt 1):1356-62.
1991: Soper J T; Berchuck A; Clarke-Pearson D L
Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.
Cancer 1991;68(4):725-9.
1991: Marks J R; Davidoff A M; Kerns B J; Humphrey P A; Pence J C; Dodge R K; Clarke-Pearson D L; Iglehart J D; Bast R C; Berchuck A
Overexpression and mutation of p53 in epithelial ovarian cancer.
Cancer research 1991;51(11):2979-84.
1991: Soper J T; Couchman G; Berchuck A; Clarke-Pearson D
The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma.
Gynecologic oncology 1991;41(3):239-44.
1991: Cliby W; Soisson A P; Berchuck A; Clarke-Pearson D L
Stage I small cell carcinoma of the vulva treated with vulvectomy, lymphadenectomy, and adjuvant chemotherapy.
Cancer 1991;67(9):2415-7.
1991: Rodriguez G C; Berchuck A; Whitaker R S; Schlossman D; Clarke-Pearson D L; Bast R C
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor.
American journal of obstetrics and gynecology 1991;164(3):745-50.
1991: Berchuck A; Rodriguez G C; Kamel A; Dodge R K; Soper J T; Clarke-Pearson D L; Bast R C
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.
American journal of obstetrics and gynecology 1991;164(2):669-74.
1991: Soper J T; Berchuck A; Clarke-Pearson D L
The clinical significance of blood transfusion at the time of radical hysterectomy.
Obstetrics and gynecology 1991;77(1):165-6.
1991: Berchuck A; Rodriguez G; Kinney R B; Soper J T; Dodge R K; Clarke-Pearson D L; Bast R C
Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.
American journal of obstetrics and gynecology 1991;164(1 Pt 1):15-21.
1990: Soper J T; Berchuck A; Olt G J; Soisson A P; Clarke-Pearson D L; Bast R C
Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma.
American journal of obstetrics and gynecology 1990;163(4 Pt 1):1204-9.
1990: Kohler M F; Berchuck A; Baker M E; Szpak C A; Soper J T; Clarke-Pearson D L
Computed tomography-guided fine-needle aspiration of retroperitoneal lymph nodes in gynecologic oncology.
Obstetrics and gynecology 1990;76(4):612-6.
1990: Hunter V J; Daly L; Helms M; Soper J T; Berchuck A; Clarke-Pearson D L; Bast R C
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
American journal of obstetrics and gynecology 1990;163(4 Pt 1):1164-7.
1990: Shpall E J; Clarke-Pearson D; Soper J T; Berchuck A; Jones R B; Bast R C; Ross M; Lidor Y; Vanacek K; Tyler T
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer.
Gynecologic oncology 1990;38(3):386-91.
1990: Berchuck A; Rodriguez G; Kamel A; Soper J T; Clarke-Pearson D L; Bast R C
Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina.
Obstetrics and gynecology 1990;76(3 Pt 1):381-7.
1990: Olt G; Berchuck A; Bast R C
The role of tumor markers in gynecologic oncology.
Obstetrical & gynecological survey 1990;45(9):570-7.
1990: Soisson A P; Geszler G; Soper J T; Berchuck A; Clarke-Pearson D L
A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy.
Obstetrics and gynecology 1990;76(1):106-9.
1990: Berchuck A; Kamel A; Whitaker R; Kerns B; Olt G; Kinney R; Soper J T; Dodge R; Clarke-Pearson D L; Marks P
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Cancer research 1990;50(13):4087-91.
1990: Soisson A P; Soper J T; Clarke-Pearson D L; Berchuck A; Montana G; Creasman W T
Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer.
Gynecologic oncology 1990;37(3):390-5.
1990: Berchuck A; Olt G J; Soisson A P; Kamel A; Soper J T; Boyer C M; Clarke-Pearson D L; Leslie D S; Bast R C
Heterogeneity of antigen expression in advanced epithelial ovarian cancer.
American journal of obstetrics and gynecology 1990;162(4):883-8.
1990: Berchuck A; Olt G J; Everitt L; Soisson A P; Bast R C; Boyer C M
The role of peptide growth factors in epithelial ovarian cancer.
Obstetrics and gynecology 1990;75(2):255-62.
1990: Berchuck A; Rubin S C; Hoskins W J; Saigo P E; Pierce V K; Lewis J L
Treatment of endometrial stromal tumors.
Gynecologic oncology 1990;36(1):60-5.
1990: Olt G J; Berchuck A; Bast R C
Gynecologic tumor markers.
Seminars in surgical oncology 1990;6(6):305-13.
1989: Soper J T; Larson D; Hunter V J; Berchuck A; Clarke-Pearson D L
Short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery.
Obstetrics and gynecology 1989;74(5):823-7.
1989: Soisson A P; Berchuck A; Lessey B A; Soper J T; Clarke-Pearson D L; McCarty K S; Bast R C
Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels.
American journal of obstetrics and gynecology 1989;161(5):1258-63.
1989: Berchuck A; Soisson A P; Olt G J; Soper J T; Clarke-Pearson D L; Bast R C; McCarty K S
Epidermal growth factor receptor expression in normal and malignant endometrium.
American journal of obstetrics and gynecology 1989;161(5):1247-52.
1989: Berchuck A; MacDonald P C; Milewich L; Casey M L
Transforming growth factor-beta inhibits prostaglandin production in amnion and A431 cells.
Prostaglandins 1989;38(4):453-64.
1989: Berchuck A; Soisson A P; Soper J T; Clarke-Pearson D L; Bast R C; McCarty K S
Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues.
Archives of pathology & laboratory medicine 1989;113(10):1155-8.
1989: Soper J T; Berchuck A; Creasman W T; Clarke-Pearson D L
Pelvic exenteration: factors associated with major surgical morbidity.
Gynecologic oncology 1989;35(1):93-8.
1989: Massad L S; Santoriello K; Berchuck A
Pneumoperitoneum due to peritoneovaginal fistula following hysterectomy.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 1989;29(3):257-61.
1989: Berchuck A; Soisson A P; Clarke-Pearson D L; Soper J T; Boyer C M; Kinney R B; McCarty K S; Bast R C
Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential.
Cancer research 1989;49(8):2091-5.
1989: Yazigi R; Berchuck A; Casey M L; MacDonald P C
Effect of epidermal growth factor on ornithine decarboxylase activity in A431 cells.
Anticancer research 1989;9(1):209-13.
1988: Berchuck A; Rubin S C; Hoskins W J; Saigo P E; Pierce V K; Lewis J L
Treatment of uterine leiomyosarcoma.
Obstetrics and gynecology 1988;71(6 Pt 1):845-50.
1988: Berchuck A; MacDonald P C; Milewich L; Casey M L
Epidermal growth factor, vanadate, and 12-O-tetradecanoylphorbol-13-acetate inhibit growth and stimulate prostaglandin E2 production in A431 cells.
Molecular and cellular endocrinology 1988;57(1-2):87-92.
1985: Berchuck A; Mullin T J
Cervical adenoid cystic carcinoma associated with ascites.
Gynecologic oncology 1985;22(2):201-11.
1984: Berchuck A; Sokol R J
Cervicovaginal fistula formation: a new complication of Shirodkar cerclage.
American journal of perinatology 1984;1(3):263-5.
1983: Berchuck A; Sokol R J
Previous cesarean section, placenta increta, and uterine rupture in second-trimester abortion.
American journal of obstetrics and gynecology 1983;145(6):766-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Andrew Berchuck

Research Profile (preview)

Disorders

Concepts & Ideas

Physiology

Procedures

Chemicals & Drugs

Anatomy

Genes & Molecular Sequences

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Andrew Berchuck (preview)

All Publications